Covid-19 roundup: Paul Hudson says US will have first dibs on Sanofi vaccine; Gilead selects 5 generic manufacturing partners for remdesivir
If Sanofi can successfully deliver a Covid-19 vaccine, the US will get first access to it, CEO Paul Hudson told Bloomberg News.
That’s because the US, through its biomedical defense agency BARDA, has invested in the technology, backing the company’s Protein Sciences subsidiary with a $30 million grant for its recombinant Covid-19 vaccine effort. Since its founding in 2005, BARDA has heavily funded both Sanofi — a French company — and Protein Sciences, which was an independent biotech until 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.